Robert Coleman
Gynecologic Oncology · Houston, TXNPI 1669570685
Payments from drug & device makers
Across 587 payments — averaging $5768.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.8M
- Merck$890K
- GSK$127K
- Clovis Oncology, Inc.$101K
- Astrazeneca UK Limited$82K
- AstraZeneca$72K
- plus $326K from 41 others
Across 23 payments — averaging $286.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
- F. Hoffmann-la Roche AG$1K
- Seagen Inc.$391
What the payments were for
- Consulting fees$576,42167%
- Speaking & faculty fees$148,99117%
- Grants$3000%
- Travel & lodging$125,24514%
- Food & beverage$12,9221%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,386,116 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in Houston
- Pamela SolimanHouston$30.7M
- Michael FrumovitzHouston$1M
- Joseph LucciHouston$292K
- David GershensonHouston$273K
- Anuj SuriHouston$250K
- Aparna KamatHouston$208K
- Maurie MarkmanHouston$204K
- Anil SoodHouston$187K
- Larissa MeyerHouston$146K
- Jan SundeHouston$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.